Arcticzymes Technologies ASA
OSE:AZT
Arcticzymes Technologies ASA
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
Strong Q4 Performance: Q4 revenue rose 39% year-on-year to NOK 34.1 million, making it the strongest quarter since Q1 2022 and the fifth strongest ever.
Improved Profitability: Q4 EBITDA nearly tripled to NOK 8.3 million, while full-year EBITDA more than doubled to NOK 12 million.
Annual Growth Resumed: Full-year revenue climbed 8% to NOK 112.6 million, or 9% to NOK 118 million including other revenues, returning the company to a growth path.
Biomanufacturing Momentum: Biomanufacturing segment led growth with 23% revenue increase for the year, driven by GMP grade nucleases and deeper CDMO integration.
Metagenomics Expansion: The company is seeing the first commercial results in metagenomics, positioning itself as a thought leader in this emerging space.
Diversified Sales: Molecular Tools Q4 sales grew 56% YoY, with less reliance on a single large customer and strong demand from kit providers and resellers.
Geographic Diversification: Excluding a headwind from one major EMEA customer, all regions saw double-digit growth rates.
Outlook and Strategy: Management targets sustainable double-digit growth, continued innovation, expansion in metagenomics and RNA applications, and expects annual—not quarterly—growth for 2026.
